LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two investor events in September. Event: H.C. Wainwright 27th Annual Global Investment Conference Type: Fireside chatDate/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET Event: Truist Securities Vir ...

EATONTOWN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), is excited to announce a strategic partnership with Coro. This partnership aims to leverage the strengths of both companies to deliver comprehensive cybersecurity solutions to a broader market. As cyber threats continue to evolve and SMBs and distributed enterprise face increasing security and compliance pres ...

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Amaero Limited (ASX: 3DA; OTCQX: AMROF), a company specializing in the research, development, manufacture, and sale of refractory metals and specialty alloy powders, has qualified to trade on the OTCQX® Best Market. Amaero LTD. upgraded to OTCQX from the OTCQB® Venture Market. Amaero Limited begins trading today on OTCQX under t ...

Presentation to be webcast live: LINK PALO ALTO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW), a provider of cybersecurity and robust solutions for drones and robotics, will present at the 2025 Annual Gateway Conference, which is being held September 3-4, 2025 at the Four Seasons Hotel in San Francisco, California. Mobilicom's management team is scheduled to present on Wednesday, September 3rd at 2:30 p.m. Pacific Time (PT). The presentation will be webcast live and avai ...

Core Insights - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [2] - The company has FDA-approved products in its pipeline, including Revuforj (revumenib) and Niktimvo™ (axatilimab-csfr) [2] - Syndax is actively participating in upcoming investor conferences to engage with stakeholders [1][3] Company Overview - Syndax Pharmaceuticals is dedicated to advancing cancer care through its innovative therapies [2] - The company is conducting several clinical trials to maximize the potential of its product pipeline [2] Upcoming Events - Syndax's CEO and management team will participate in Citi's 2025 BioPharma Back to School Conference on September 2, 2025 [3] - The company will also present at H.C. Wainwright's 27th Annual Global Investment Conference on September 8, 2025 [3]

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in three upcoming investor conferences in September 2025 as follows: Cantor Healthcare Conference: fireside chat at 8:00 am ET on Thursday, September 4th and available to host inve ...

Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA, a leading provider of global commercial services to the life ...

Core Points - DFDS has entered into a mutual space charter agreement with TT Line to enhance the efficiency and scope of its Baltic Sea ferry network [1][7] - The agreement will be effective for freight on 1 October 2025 and for passengers on the Karlshamn-Klaipeda route on 1 October 2025, and on the other two routes on 1 November 2025 [2][7] - The agreement allows customers to board the next available sailing regardless of the operator, while maintaining control over commercial activities with customers [2][3] Summary by Sections Agreement Details - The space charter agreement covers the combined freight and passenger route Karlshamn-Klaipeda and grants DFDS access to TT Line routes Klaipeda-Trelleborg and Klaipeda-Travemünde [1][7] - The agreement is expected to increase sailing frequency for customers on the Karlshamn-Klaipeda route while reducing the number of sailings needed, thus helping to lower emissions [3][4] Company Overview - DFDS operates a transport network in Europe with an annual revenue of DKK 30 billion and employs 16,500 full-time staff [5] - The company was founded in 1866 and is headquartered in Copenhagen, focusing on ferry, road, and rail transport solutions [6]

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference: Fireside chat at 4:00 p.m. ET on Tuesday, September 2, 2025, in Boston, MA, during which the company plans to highlight preclinical data supporting its non-viral delivery platform l ...

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile observed in study participants with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort Dose expansion phase of study will investigate MT-601 at pre-specified maximum dose in patients ...